There remains a significant unmet medical
need for reliable and accurate diagnostics to enable early diagnosis and disease-modifying treatments that slow the progress of
We have assembled an outstanding management
team with relevant scientific, clinical and regulatory expertise. Our scientific founders, Dr. Jean-Marie Lehn, Dr. Claude
Nicolau, Dr. Roscoe Brady and Dr. Fred van Leuven, are regarded as pioneers in their respective scientific domains, including
in the study of AD. Our co-founder and Chief Executive Officer, Dr. Andrea Pfeifer, a pharmacologist with a Ph.D. in cancer
research and former National Institute of Health researcher, has a 30 year track record in product innovation and implementation
and was formerly head of Nestlé Global Research and the co-founder of Nestlé Venture Fund. In January 2019, we appointed
Dr. Marie Kosco-Vilbois to be our Chief Scientific Officer. Dr. Kosco-Vilbois has more than 20 years of experience in various aspects
of discovery research and drug development, including working on multiple drug development programs.
Figure 3: AC Immune 3-pillars business
Our goal is to become a global leader in
precision medicine for the treatment of neurodegenerative diseases. To that aim, we are executing a clear business strategy around
three pillars: (i) Alzheimer’s disease, (ii) other significant neurodegenerative diseases and neuro-orphan indications, and
The first pillar is Alzheimer’s disease,
where we are developing best-in-class late stage assets, preventive or therapeutic vaccines in partnership or as fully owned assets
and where we are working to establish a pipeline of disease modifying small molecules.
The second pillar is other non-AD neurodegenerative
diseases and neuro-orphan indications, where we aim to discover therapeutic treatments for Parkinson’s disease and leverage
our AD therapeutics in Down syndrome, progressive supranuclear palsy (PSP) and other neuro-orphan diseases.
The third pillar is represented by diagnostics,
where we accelerate the diagnostic pipeline to late stage development and use the diagnostics to improve clinical trials and to
establish external partnerships.
Key elements of our strategy continue to